As of September 27, 2026, RegenLab USA has an active Form S-1 registration statement on file with the SEC for an initial public offering on Nasdaq under the ticker RGNA, according to Renaissance Capital's report on September 25, 2026. The filing seeks to raise up to $35 million, with StoneX Financial Inc. acting as sole book-running manager. RegenLab USA is a regenerative-medicine device maker founded in Switzerland in 2003 and now based in Jersey City, New Jersey; it filed confidentially with the SEC on October 20, 2025, and reported $54 million in revenue for the 12 months ended June 30, 2026, Renaissance Capital said. TradingView's September 26, 2026 coverage described the S-1 as covering point-of-care platelet-rich plasma (PRP) and hyaluronic acid (HA) regenerative-medicine devices, with StoneX as sole bookrunner and no price range or share count specified yet. SEC EDGAR is the primary record for the US filing; Segmara does not sell, broker, or predict outcomes for any offering.
Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases. Nothing here is investment advice.
Key points
A filed S-1, not yet a set date
RegenLab USA has an active Form S-1 registration statement on file with the SEC, seeking to raise up to $35 million and list on Nasdaq under the ticker RGNA, Renaissance Capital reported on September 25, 2026. StoneX Financial Inc. is acting as sole book-running manager. A filed S-1 is a real step toward a public listing, but it is not a confirmed date: the document does not yet include a price range or a share count, TradingView noted in its September 26, 2026 coverage.
From a confidential draft to a public filing
RegenLab USA first filed confidentially with the SEC on October 20, 2025, according to Renaissance Capital. Moving from a confidential draft to a public Form S-1 is itself a step forward, though neither a price range nor a listing date has been set as of the latest filing.
The company is based in Jersey City, New Jersey, and was founded in Switzerland in 2003, per the same report.
The business behind the ticker
RegenLab USA makes point-of-care regenerative-medicine devices built around platelet-rich plasma (PRP) and hyaluronic acid (HA), according to TradingView's September 26, 2026 description of the filing. Renaissance Capital reported the company booked $54 million in revenue for the 12 months ended June 30, 2026.
Track SEC EDGAR directly for the S-1's public filing record and any amendments; EDGAR covers only US filings, and a Nasdaq listing has not been finalized as of the latest review.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-regenlab-usa-ipo
Stable URL path for AI and search extraction.
Article title
When Will RegenLab USA IPO? Its S-1 Targets Nasdaq as RGNA
Main page topic.
Attached public sources
2
Number of citation links rendered at the bottom of the article.
Segmara listed companies
51
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Listings without an indicative price
14
Catalogue listings where a public price is intentionally not invented.
Data fingerprint chart
Visible pricing coverage72%
37 of 51 listings show a mark
Stage
Timing
Price / valuation signal
Interpretation
Chart metric
Score
Interpretation
Visible pricing coverage
72 / 100
37 of 51 listings show a mark
Analytical lens
Search intent
Searches like 'When Will RegenLab USA IPO? Its S-1 Targets Nasdaq as RGNA' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
Segmara is an independent research site. It does not sell, broker, or arrange share purchases, and nothing on this page is investment advice.
How a company reaches a US listing
The SEC filing trail
DraftThe company can first submit a draft registration statement (DRS) for confidential SEC review.
S-1 or F-1The registration statement goes public on SEC EDGAR: Form S-1, or Form F-1 for many foreign companies. A company that used a draft must file publicly at least 15 days before its roadshow.
AmendmentsS-1/A or F-1/A amendments answer SEC comments, and one of them adds the expected price range.
PricingOnce the SEC declares the registration effective, the company sets the price with its underwriters and files the final prospectus, usually a 424B4.
First tradeThe shares start trading on the exchange named in the prospectus, such as Nasdaq or the NYSE.
Segmara Pro checks SEC EDGAR for RegenLab USA filings every weekday and posts an alert in the members forum when one of these public filings appears. You can also check yourself with EDGAR full-text search.
RegenLab USA has a Form S-1 on file with the SEC as of Renaissance Capital's September 25, 2026 report, seeking to raise up to $35 million and list on Nasdaq under the ticker RGNA, with StoneX Financial as sole book-running manager.
The Jersey City, New Jersey-based company, founded in Switzerland in 2003, filed confidentially on October 20, 2025, and booked $54 million in revenue for the 12 months ended June 30, 2026, per Renaissance Capital.
TradingView reported on September 26, 2026 that the S-1 covers point-of-care PRP and HA regenerative-medicine devices, with no price range or share count set yet.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Segmara Pro: a weekly IPO brief plus SEC filing alerts for 60+ companies, including RegenLab USA, from automated EDGAR checks every weekday, posted in the members forum; 7-day free trial, then $15 a month (plus any applicable tax). Research only, no share sales.
Can retail investors track private-company shares on Segmara?
Yes. The free pre-IPO tracker sends indicative marks by email, with no card and no documents. Segmara does not sell, broker, or arrange share purchases.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes research simpler: anyone can follow named private companies for free, by email.
What is the easiest next step?
Open the free pre-IPO tracker first, email only. The IPO calendar is free, and Segmara Pro adds a weekly IPO brief.
Has RegenLab USA confirmed an IPO date?
No specific listing date has been confirmed. RegenLab USA filed a Form S-1 to list on Nasdaq under RGNA, according to Renaissance Capital's September 25, 2026 report, but the filing does not set a date, price range, or share count.
What does RegenLab USA make?
RegenLab USA makes point-of-care platelet-rich plasma (PRP) and hyaluronic acid (HA) regenerative-medicine devices, per TradingView's September 26, 2026 description of the S-1.
How much is RegenLab USA trying to raise, and who is running the deal?
The Form S-1 seeks to raise up to $35 million, with StoneX Financial Inc. named as sole book-running manager, according to Renaissance Capital.
Can I buy RegenLab USA shares before the IPO?
Not through Segmara. Segmara does not sell, broker, or arrange purchases of RegenLab USA shares, and any private-share offer you encounter should be verified independently before you rely on it.
Next step
Track private-market prices free.
If this article helped explain RegenLab USA, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account.
Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.